Ibrutinib Intermediate CAS 330792-70-6 Purity >98.0% (HPLC)

Short Description:

5-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazole-4-Carbonitrile

CAS: 330792-70-6

Purity: >98.0% (HPLC)

Appearance: Off-White to Light Yellow Powder

Intermediate of Ibrutinib (CAS: 936563-96-1) 

Contact: Dr. Alvin Huang    

Mobile/Wechat/WhatsApp: +86-15026746401 

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Intermediates of Ibrutinib:

Chemical Properties:

Chemical Name 5-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazole-4-Carbonitrile
Synonyms Ibrutinib Intermediate N-3; 3-Amino-5-(4-Phenoxyphenyl)pyrazole-4-Carbonitrile; 3-Amino-4-Cyano-5-(4-Phenoxyphenyl)pyrazole; 5-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazole-4-Carbonitrile
CAS Number 330792-70-6 
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C16H12N4O
Molecular Weight 276.29
Density 1.37±0.10 g/cm3
COA & MSDS Available
Origin Shanghai, China
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Off-White to Light Yellow Powder 
Purity / Analysis Method >98.0% (HPLC)
Loss on Drying <1.00%
Residue on Ignition <0.50%
Total Impurities <2.00%
Heavy Metals (as Pb) <20ppm
1 H NMR Spectrum Consistent with Structure
Test Standard Enterprise Standard
Usage Intermediate of Ibrutinib (CAS: 936563-96-1)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

www.ruifuchem.com

330792-70-6 - Application:

5-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazole-4-Carbonitrile (CAS: 330792-70-6) is an intermediate of Ibrutinib (CAS: 936563-96-1). Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling.

  • Write your message here and send it to us